An Observational Study of Patients With Autoimmune Disease

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTarget PharmaSolutions, Inc.

About this trial

TARGET-AUTOIMMUNE is an observational research study to conduct a comprehensive review of outcomes for patients with autoimmune and related diseases. .

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Death

Manual removal (sponsor or site request)

No EHR interface encounter > 3 years

Adult patients diagnosed and managed for these conditions invited to participate

Trial population

The study will include adults who are being managed for autoimmune disease

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

500,000 Participants
are grouped into 2 trial groups
Group A: Disease Cohort
Group B: Engaged Cohort

Trial outcomes

Primary outcomes

1

To characterize the natural history of disease in patients with autoimmune disease of various etiologies.

Time frame
15 Years
2

To assess safety and effectiveness of autoimmune disease treatments and treatments for complications of any related conditions

Time frame
20 Years

Secondary outcomes

1

To evaluate provider management practices in the treatment of patients with autoimmune diseases

Health care provider type, clinic setting, reason for initiating/not initiating/adjusting dosing of treatments, reason for discontinuing/switching treatments, and monitoring outcomes on and off treatment, will be captured as available in the provided EHR and/or through linked data. Disease-specific quality measures will be selected and evaluated.

Time frame
15 Years
2

To evaluate longitudinal and patient reported outcomes in patients with autoimmune diseases

Longitudinal clinical outcomes and disease progression will be assessed. Self-reported patient health measures collect information directly from patients to measure physical, mental, and social health. These measures can help clinicians better understand how the disease state and/or various treatments affect what patients are able to do and the symptoms they experience beyond what is typically derived and reported in the EHR as part of traditional clinical evaluations. The information can also be used to help patients make informed decisions about their healthcare and treatment options.

Time frame
15 Years
3

To select and evaluate quality of care measures for patients with autoimmune diseases

1. Identify and select best practices in care of patients with autoimmune diseases 2. Develop a technology infrastructure to evaluate quality measures to support clinicians.

Time frame
15 Years

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: